Edition:
India

Radius Health Inc (RDUS.OQ)

RDUS.OQ on NASDAQ Stock Exchange Global Market

32.97USD
1:30am IST
Change (% chg)

$0.77 (+2.39%)
Prev Close
$32.20
Open
$32.37
Day's High
$33.18
Day's Low
$32.18
Volume
131,694
Avg. Vol
274,747
52-wk High
$49.15
52-wk Low
$24.68

Select another date:

Sat, Mar 31 2018

BRIEF-Radius Health Initiates Phase 3 Trial Of Abaloparatide Injection For Male Osteoporosis

* RADIUS HEALTH INITIATES PHASE 3 CLINICAL TRIAL OF ABALOPARATIDE INJECTION FOR THE TREATMENT OF MALE OSTEOPOROSIS Source text for Eikon: Further company coverage:

BRIEF-Radius Health Provides Update On CHMP Opinion For Abaloparatide-SC

* RADIUS HEALTH PROVIDES UPDATE ON CHMP OPINION FOR ABALOPARATIDE-SC

BRIEF-Radius Health Reports Q4 Loss Per Share $1.59

* RADIUS HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Radius Health Expects CHMP To Issue Opinion Regarding Marketing Authorization Application Of Abaloparatide-Sc during H1 2018

* RADIUS HEALTH ANNOUNCES THAT THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) WILL ISSUE A THIRD DAY-180 LIST OF OUTSTANDING ISSUES IN ITS REGULATORY REVIEW OF ABALOPARATIDE-SC, A BONE BUILDING AGENT FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURE

BRIEF-Point72 Asset Management Reports 5.1 Percent Passive Stake In Radius Health

* POINT72 ASSET MANAGEMENT, L.P REPORTS 5.1 PERCENT PASSIVE STAKE IN RADIUS HEALTH INC AS OF NOVEMBER 24, 2017 - SEC FILING‍​ Source text: (http://bit.ly/2iXLIQS) Further company coverage:

BRIEF-Radius Health reports Q3 loss per share $1.31

* Radius Health Inc reports third quarter 2017 financial and operating results and provides business update

Select another date: